STALLERGENES-GREER
Stallergenes Greer, a biopharmaceutical company specialising in treatments for respiratory allergies, announces the expansion of the supply of subcutaneous products (SCIT), further broadening its offering to patients and the medical community through a sustained investment in quality and operational excellence.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200518005223/en/
“Stallergenes Greer is committed to the disciplined execution of the company’s strategy and is well advanced on its transformation journey. Our robust fundamentals, investments in quality, and commitment to operational excellence continue to yield results as evidenced by the expansion of SCIT products, the widening of our portfolio and the solidifying of our leadership positions in various markets. We can be proud of our achievements and look ahead with confidence,” declares Michele Antonelli, Chief Executive Officer.
Acceleration of SCIT production
In April 2020, the French Agency for Medicines and Health (ANSM) lifted its injunction, which primarily impacted the production of subcutaneous products for the Europe and International region. SCIT production will fully resume in Antony, France, in the coming weeks, starting with skin prick tests (Alyostal® pricks) for diagnosis, and Alustal® for the treatment of patients with allergies. SCIT production in the US, where Stallergenes Greer continues to lead the market, has remained fully operational and was not part of the injunction.
With sustained investments in its global manufacturing capabilities, Stallergenes Greer operates state-of-the-art manufacturing and quality systems that meet the highest product quality standards.
Stallergenes Greer intends to further provide injectable forms with the resumption of Phostal®.
SCIT products meet the needs of patients whose profile and lifestyle require an alternative access to treatment and delivery mode, longer intervals between treatment, or monitoring of adherence by their physician.
Further broadening the allergen immunotherapy treatment portfolio
Stallergenes Greer remains determined to offer an extensive portfolio of treatment solutions tailored to each patient profile and to each market, including injectable therapies, sublingual therapies such as drops and tablets, venoms and diagnostics. From diagnosis to treatment, Stallergenes Greer’s portfolio is designed to ensure the consistency of its products in terms of active ingredients and high-quality standards. It allows physicians to choose the administration method which is best suited to each patient’s needs and lifestyle.
In 2019 alone, the company added 15 new Staloral® allergen references to its sublingual portfolio and will launch another 10 references in 2020.
Stallergenes Greer, also continued to enhance its tablet offering which already includes Oralair® for the treatment of grass pollen allergies and Actair® for the treatment of house dust mite allergies, which is distributed in selected countries of the Asia-Pacific region.
The company recently submitted a European marketing application authorisation for its house dust mite allergy immunotherapy tablet. The tablet is also under New Drug Submission review by Health Canada.
Stallergenes Greer is delivering on the disciplined execution of its strategy of providing people with allergies a broad range of personalised treatment options, which will make it both a company with a complete portfolio and a valued partner for patients and the medical community.
ABOUT STALLERGENES GREER Ltd
Headquartered in London (UK), Stallergenes Greer Ltd is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Stallergenes Greer Ltd is the parent company of Greer Laboratories, Inc. (whose registered office is in the United States) and Stallergenes SAS (whose registered office is in France).
Additional information is available at https://www.stallergenesgreer.com/
View source version on businesswire.com: https://www.businesswire.com/news/home/20200518005223/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Outreach Bolsters its EMEA Presence and Enhances Customer Experience with New General Manager5.11.2025 11:00:00 CET | Press release
Former Box VP Paul Ditchfield joins revenue orchestration leader to accelerate growth, increase AI adoption, and drive revenue for enterprise companies Outreach, the AI Revenue Workflow Platform, is amplifying its EMEA presence by hiring Paul Ditchfield as its new General Manager of EMEA. This move strengthens Outreach’s already vast presence in EMEA with offices in London and Prague, and a data center in Ireland. Ditchfield will lead Outreach’s rapidly growing EMEA team, working closely with customers such as SAP, Siemens, and Omniplex, and expanding Outreach’s presence across EMEA. With twenty-five years of experience in enterprise sales, Ditchfield brings a proven track record of leading revenue teams at Box, ON24, Adobe, and Global Graphics Software. “The rapid rise of AI advancements in EMEA makes it an even more exciting time for the revenue orchestration space,” said Abhijit Mitra, Outreach CEO. “Paul’s leadership and deep understanding of the enterprise software market will be
Corona Cero Brings Golden Moments to the Mountains of Milano Cortina 20265.11.2025 10:30:00 CET | Press release
First-ever no-alcohol beer sponsor of Olympic Winter Games celebrates “For Every Golden Moment” platform with consumers globally As the 100-day countdown to the Olympic Winter Games continues, and in a year the global Corona brand is celebrating its 100th anniversary, Corona Cero is officially set to bring golden moments to the slopes of Milano Cortina 2026. As the first no-alcohol beer sponsor of the Winter Olympics, the brand is revving up its “For Every Golden Moment” global platform to invite consumers to celebrate every golden moment any time, any season. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105994873/en/ Corona Cero's "For Every Golden Moment" Olympic Winter Games What began at the Olympic Games Paris 2024, Corona Cero’s Olympics partnership reinforces that beer and sports are better together by offering consumers more choices for any occasion. Corona Cero’s role reflects AB InBev and the International Oly
Nissan and Infobip Achieve 200% Increase in Engagement with AI-Driven WhatsApp Campaign5.11.2025 10:00:00 CET | Press release
AI-powered voice game sets new standard for digital marketing Nissan has redefined customer engagement by partnering with global cloud communications platform Infobip to pioneer a first-of-its-kind Agentic AI campaign. Nissan Kingdom of Saudi Arabia (KSA) leveraged Infobip’s newly launched Conversational AI Gamification, an AI-powered toolset that enables playful, immersive experiences across messaging channels. The marketing campaign utilized Infobip's Vocalize feature, an AI-powered voice game where users competed to win a brand-new Nissan Magnite. Participants used their voices to match an audio waveform to the outline of a car, directly within WhatsApp. This innovative approach transformed lead generation into an engaging competition, driving user participation and brand interaction. For Nissan KSA, the campaign enhanced brand awareness, increased engagement time, simplified lead acquisition, and stronger brand affinity. The innovative format also provided a cost-effective acquisit
NHOA Energy Commissions a 50 MWh Energy Storage System in Sicily5.11.2025 08:45:00 CET | Press release
The Vicari BESS, supplied on a turnkey EPC basis, integrates advanced storage technologies with two of ERG’s onshore wind farms, strengthening Sicily’s role in Italy’s energy transition NHOA Energy, a global provider of utility-scale energy storage systems, announces the commissioning of a 50 MWh Battery Energy Storage System (BESS) in Vicari, Sicily. Developed for ERG, a leading international independent renewable power producer, this project marks a major milestone in the deployment of large-scale storage systems supporting grid stability and renewable energy integration. Located at ERG’s substation connected to the Vicari and Roccapalumba wind farms, the system has a power capacity of 12.5 MW and a nominal storage capacity of 50 MWh, enabling it to store renewable energy for up to four hours. Fully designed, built, and commissioned by NHOA Energy as both BESS supplier and EPC (Engineering, Procurement and Construction) contractor, the project integrates proprietary Power Conversion
Galderma Receives U.S. FDA Approval for Restylane® Lyft™ for the Enhancement of the Chin Profile5.11.2025 07:00:00 CET | Press release
This approval is based on results showing the safety and effectiveness of Restylane Lyft in enhancing the chin profile, with high patient satisfaction and long-lasting results1,2 Restylane Lyft is the only hyaluronic acid (HA) injectable approved to treat the midface, facial folds and wrinkles, back of hands and the chin, with consistent results observed across diverse patient types1,2 Galderma’s Restylane portfolio, including Restylane Lyft, is supported by decades of clinical evidence and real patient experiences with over 77 million treatments delivered worldwide3,4 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Restylane Lyft with Lidocainefor augmentation of the chin region to improve the chin profile in patients over the age of 21 with mild-to-moderate chin retrusion.2 Restylane Lyft is a versatile HA injectable with over 20 years of worldwide safety data, which is also
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom